Linked Life Data

16422311

Source:http://linkedlifedata.com/resource/pubmed/id/16422311

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2006-1-20
pubmed:abstractText
Estimation of sample size for long-term studies of neuroprotection in Parkinson's disease requires information on expected clinical decline. Values may be obtained by analyzing existing long-term data sets or by prediction models of clinical decline applied to available data from shorter-term trials. The most commonly used measure to track clinical decline is the Unified Parkinson's Disease Rating Scale (UPDRS) but this measure is also affected by symptomatic therapy. Models can help better understand behavior of the UPDRS after initiation of symptomatic therapy when scores will improve and eventually start deteriorating again.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1740-7745
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
509-18
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials.
pubmed:affiliation
Dept of Biostatistics, Bioinformatics & Epidemiology, Medical University of South Carolina, 135 Cannon St. Suite 303, Charleston, SC 29425, USA. guimarap@musc.edu
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural